AnaptysBio, Inc. (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus increased their price target on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. Credit Suisse Group increased their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Robert W. Baird started coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $34.50.

Shares of AnaptysBio (NASDAQ ANAB) traded up 2.07% during midday trading on Tuesday, hitting $25.18. The company had a trading volume of 170,214 shares. The stock’s market capitalization is $512.21 million. AnaptysBio has a one year low of $15.17 and a one year high of $30.71. The stock’s 50-day moving average price is $23.98 and its 200-day moving average price is $24.68.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7 million during the quarter, compared to the consensus estimate of $3.45 million. Analysts predict that AnaptysBio will post ($1.96) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/anaptysbio-inc-anab-cut-to-hold-at-zacks-investment-research/1530248.html.

In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at $40,862,344.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,133,940 shares of company stock valued at $24,223,316.

A number of institutional investors have recently added to or reduced their stakes in ANAB. Bank of America Corp DE bought a new position in AnaptysBio during the first quarter worth about $123,000. DAFNA Capital Management LLC boosted its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares during the period. New York State Common Retirement Fund acquired a new stake in shares of AnaptysBio during the second quarter worth $168,000. TIAA CREF Investment Management LLC acquired a new stake in shares of AnaptysBio during the first quarter worth $227,000. Finally, Teachers Advisors LLC boosted its stake in shares of AnaptysBio by 23.4% in the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after buying an additional 1,807 shares during the period. 71.35% of the stock is owned by institutional investors.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.